EIF1B-AS1: A Potential Drug Target and Biomarker (G440952)

Target Name: EIF1B-AS1

NCBI ID: G440952

Other Name(s): EIF1B antisense RNA 1

EIF1B-AS1: A Potential Drug Target and Biomarker

Introduction

EIF1B-AS1, also known as EIF1B-AS1 Antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. EIF1B-AS1 is expressed in most tissues and cells, and its levels are regulated by various factors, including gene expression, DNA methylation, and post-transcriptional modifications.

Disease-RelatedExpression

EIF1B-AS1 has been observed to be involved in several diseases, including cancer. For instance, studies have shown that EIF1B-AS1 is abnormally expressed in various types of cancer, such as breast, ovarian, and colorectal cancer. Additionally, eIF1B-AS1 has been associated with cancer-related behaviors, such as cell motility, invasion, and metastasis.

Furthermore, overexpression of EIF1B-AS1 has been shown to promote the development of cancer by inhibiting the tumor suppressor protein, p53. This is because EIF1B-AS1 can bind to p53 and prevent it from activating target genes that are involved in cell growth and apoptosis.

Biomarker Potential

EIF1B-AS1 has also been identified as a potential biomarker for cancer. The expression of EIF1B-AS1 has been shown to be associated with the severity of cancer-related symptoms, such as pain, nausea, and fatigue. Additionally, higher EIF1B-AS1 expression has been associated with poor prognosis in cancer patients.

Drug Target Potential

The potential drug target for EIF1B-AS1 is related to its role in cancer development and progression. Specifically, studies have shown that EIF1B-AS1 can inhibit the effects of chemotherapy drugs, such as doxorubicin, by preventing them from binding to p53. This is because EIF1B-AS1 can bind to p53 and prevent it from activating target genes that are involved in cell growth and apoptosis, thereby inhibiting the effects of chemotherapy drugs.

In addition, EIF1B-AS1 has also been shown to be involved in the regulation of cell cycle progression. Specifically, EIF1B-AS1 has been shown to promote the G1 phase and the S phase of the cell cycle, which are critical for cell growth and development.

Conclusion

In conclusion, EIF1B-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its expression is regulated by various factors, including gene expression, DNA methylation, and post-transcriptional modifications. Furthermore, studies have shown that EIF1B-AS1 is involved in the regulation of cell cycle progression and has been associated with cancer-related behaviors. Therefore, EIF1B-AS1 may be a promising drug target for cancer treatment.

Protein Name: EIF1B Antisense RNA 1

More Common Targets